The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

White Spot Lesions Treatment in Orthodontic (WSL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06051981
Recruitment Status : Not yet recruiting
First Posted : September 25, 2023
Last Update Posted : September 25, 2023
Sponsor:
Information provided by (Responsible Party):
Samira Fawaz M Algasn, Riyadh Elm University

Brief Summary:

The study aims to investigate the effectiveness of a new treatment for demineralized white spot lesions (WSLs) after fixed appliance therapy. The trial will consist of four parallel groups: control, Fluoride Varnish (FV), Casein Phosphopeptide-Amorphous Calcium Phosphate (CPP-ACP), and Resin Infiltration (RI) groups. Patients will be recruited from Riyadh Elm University's electronic record system and contacted by phone. They will be given an appointment to visit the dental clinic.

A total of 22 patients with WSLs will be selected for the study. Two examiners will perform dental examinations using a dental mirror and a ball-ended probe to code the WSL against the ICDAS system. The level of agreement between the two examiners will be assessed using reliability analysis, with an agreement level of above 80% considered.

Buccal WSLs will be defined as those that extend from the center of the buccal to either the mesial or distal surface. WSLs coded 3 or higher will be excluded from further examination and treated accordingly.


Condition or disease Intervention/treatment Phase
White Spot Lesion Drug: 5% sodium fluoride Drug: Intensive 5% sodium fluoride Drug: Casein Phosphopeptide-Amorphous Calcium Phosphate Drug: Resin infiltration Phase 4

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Once the FV has been applied, the examiners at Riyadh Elm University will do a visual inspection and take LF measurements (T2) on all the areas that were marked as WSL on the initial photos. The LF measurement will be carried out by the same inspectors who carried out the visual inspection.

At the end of treatment for groups II, III, IV, a visual examination and LF measurements (T2) will be conducted by the same examiners. At the next inspection (after 3 months (T3)), LF measurements will be carried out on all areas that were marked as WSL on the original photos, whether they are still existing WSL areas or they will be changed to WSL free areas.

Masking: Triple (Participant, Investigator, Outcomes Assessor)
Masking Description: A web based research randomizer software will be used to generate a random sequence number to allocate the participants to different groups. The allocation will be kept concealed from patients and examiners using sequentially numbered identical containers containing experimental materials (remineralizing agents) to ensure the double blindness of the study.
Primary Purpose: Treatment
Official Title: The Effect of Fluoride Varnish, Casein Phosphopeptide-Amorphous Calcium Phosphate, and Resin Infiltration in the Treatment of White Spot Lesions After Orthodontic Therapy: A Randomized Controlled Trial
Estimated Study Start Date : October 2023
Estimated Primary Completion Date : February 2024
Estimated Study Completion Date : March 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Rashes

Arm Intervention/treatment
Experimental: Fluoride Varnish (control)
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. In group I, FV EnamelastTM will be applied to all teeth using compressed air and cotton rolls, leaving them to dry for one minute. Patients will be advised to avoid eating, drinking, or brushing for 3-4 hours after application.
Drug: 5% sodium fluoride
a flavored xylitol-sweetened, 5% sodium fluoride in a resin carrier delivered in a 1.2 ml syringe or in a 0.4 ml unit, Ultradent, USA) will be applied on all teeth according to the manufacturer's instructions.
Other Name: FV EnamelastTM

Experimental: Intensive Fluoride Varnish
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Patients in group II Intensive FV will be applied three times a week for a week (every two days).
Drug: Intensive 5% sodium fluoride
Intensive FV will be applied three times a week for a week (every two days).
Other Name: EnamelastTM

Experimental: Casein Phosphopeptide-Amorphous Calcium Phosphate
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group III (CPP-ACP) uses Tooth Mousse® for 12 weeks, will be applied after daily brushing with traditional toothpaste, left intact for 180 seconds, and rinsed with distilled water.
Drug: Casein Phosphopeptide-Amorphous Calcium Phosphate
for 12 weeks. A thin layer from Tooth Mousse™ will be applied to the teeth after daily brushing with traditional toothpaste and left intact for 180 seconds before rinsing with distilled water
Other Name: (CPP-ACP), Tooth Mousse® (MI Paste®) (GC Corporation, Tokyo, Japan)

Experimental: Resin Infiltration
The study involves 22 patients with WSLs at Riyadh Elm University's dental clinics, who will undergo dental examinations and receive ICDAS codes. Group IV uses ICON® resin infiltration, applying a 15% hydrochloric acid solution, rinsing with water, drying, and applying ICON-Dry. Excess resin is removed, and a light curing process is performed. The roughened enamel surface is polished using composite resin polish discs and cups.
Drug: Resin infiltration
resin infiltration will be applied as specified by the manufacturer.
Other Name: ICON® (DMG, Hamburg, Germany)




Primary Outcome Measures :
  1. Change in mineral contents of enamel [ Time Frame: Baseline pre-treatment (T1), immediately post-treatment (T2), and three months post-treatment (T3) ]
    The maximum light fluorescence value for each tooth with a white spot lesion will be determined using a DIAGNODent flat tip, following manufacturer's instructions. The DIAGNOdent scale will be used to measure the mineral content of enamel, with values ranging from 0 to 20.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Post orthodontic patients with one WSLs on buccal surface of tooth with ICDAS Code 1 or 2.
  2. Agreeing to participate in the study by singing the study informed consent.
  3. For younger patients parents agree to provide consent for child participation in the study.

Exclusion Criteria:

  1. Developmental defects of dental hard tissue
  2. Patients who have systemic disease or under medications that usually cause an increased risk of oral caries.
  3. Patients who are allergic to Fluoride varnish, CPP-ACP and resin infiltration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06051981


Contacts
Layout table for location contacts
Contact: Samira Algasn, BDS ‭966500929996‬ samira.m.algasn2021@student.riyadh.edu.sa

Sponsors and Collaborators
Riyadh Elm University
Investigators
Layout table for investigator information
Principal Investigator: Samira Algasn, BDS Riyadh Elm University
Additional Information:
Publications of Results:

Other Publications:

Layout table for additonal information
Responsible Party: Samira Fawaz M Algasn, Postgraduate Student, Riyadh Elm University
ClinicalTrials.gov Identifier: NCT06051981    
Other Study ID Numbers: FPGRP/2023/780
First Posted: September 25, 2023    Key Record Dates
Last Update Posted: September 25, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Keywords provided by Samira Fawaz M Algasn, Riyadh Elm University:
Fixed orthodontic Appliances
White Spot Lesion
Fluoride Varnish
Casein Phosphopeptide-Amorphous Calcium Phosphate
Resin Infiltration
Laser Fluorescence
Additional relevant MeSH terms:
Layout table for MeSH terms
Exanthema
Skin Diseases
Listerine
Calcium
Fluorides
Sodium Fluoride
Caseins
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Cariostatic Agents
Protective Agents
Anti-Infective Agents, Local
Anti-Infective Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action